Aratana Therapeutics Inc (NASDAQ:PETX) – Stock analysts at William Blair dropped their FY2020 earnings estimates for shares of Aratana Therapeutics in a note issued to investors on Monday, according to Zacks Investment Research. William Blair analyst J. Kreger now anticipates that the biopharmaceutical company will post earnings of $0.79 per share for the year, down from their prior forecast of $0.81.
Other research analysts also recently issued research reports about the company. Stifel Nicolaus reiterated a “hold” rating and set a $6.00 price target on shares of Aratana Therapeutics in a research note on Monday, December 18th. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 21st. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. Jefferies Group reiterated a “buy” rating and set a $8.00 price target on shares of Aratana Therapeutics in a research note on Friday, November 3rd. Finally, ValuEngine downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $8.55.
Shares of Aratana Therapeutics (NASDAQ PETX) traded up $0.14 during trading on Tuesday, hitting $5.25. The stock had a trading volume of 330,200 shares, compared to its average volume of 685,471. Aratana Therapeutics has a 1 year low of $4.81 and a 1 year high of $8.34. The stock has a market cap of $225.75, a price-to-earnings ratio of -3.62 and a beta of 3.36. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26.
Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The firm had revenue of $6.16 million during the quarter, compared to analyst estimates of $6.47 million. During the same period last year, the firm posted ($0.38) EPS. The business’s revenue was up 1440.0% compared to the same quarter last year.
In related news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the transaction, the insider now directly owns 529,359 shares of the company’s stock, valued at approximately $3,705,513. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.70, for a total value of $5,075,941.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,057,032 shares of company stock valued at $6,186,791. Corporate insiders own 5.20% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in PETX. Vanguard Group Inc. raised its holdings in shares of Aratana Therapeutics by 13.9% during the 1st quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after buying an additional 235,208 shares in the last quarter. Geode Capital Management LLC increased its stake in Aratana Therapeutics by 4.5% in the 1st quarter. Geode Capital Management LLC now owns 243,352 shares of the biopharmaceutical company’s stock worth $1,289,000 after purchasing an additional 10,465 shares during the period. Dimensional Fund Advisors LP increased its stake in Aratana Therapeutics by 85.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock worth $680,000 after purchasing an additional 59,181 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Aratana Therapeutics by 17.9% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after purchasing an additional 3,883 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Aratana Therapeutics by 8.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 65,415 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 5,165 shares during the period. 73.76% of the stock is currently owned by institutional investors.
WARNING: “FY2020 EPS Estimates for Aratana Therapeutics Inc Cut by Analyst (PETX)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/fy2020-eps-estimates-for-aratana-therapeutics-inc-decreased-by-analyst-petx.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.